April 25, 2007 — CV Therapeutics Inc. has announced that data from the MERLIN TIMI-36 study will be published in this week's issue of The Journal of the American Medical Association (JAMA). The company plans to ask the FDA to modify the existing product labeling for Ranexa (ranolazine extended-release tablets) by reducing cautionary language and expanding the indication to include first-line angina.
